Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma

Haematologica. 2017 Jul;102(7):e261-e265. doi: 10.3324/haematol.2016.162321. Epub 2017 Apr 6.

Authors

Emma C Scott¹, Richard T Maziarz², Stephen E Spurgeon², Eva Medvedova², James Gajewski², Shara Reasor-Heard², Byung Park³, Anne Kratz², George V Thomas⁴, Marc Loriaux⁴, Michael Cascio⁴, Jennifer Podolak⁴, Miranda Gordon², Jennifer Botelho², Edward Stadtmauer⁵, Ravi Amaravadi⁵, Dan T Vogl⁵

Affiliations

¹ The Department of Medicine and the Knight Cancer Institute at Oregon Health & Science University, the University of Pennsylvania, PN, USA scottem@ohsu.edu.
² The Department of Medicine and the Knight Cancer Institute at Oregon Health & Science University, the University of Pennsylvania, PN, USA.
³ Public Health and Preventative Medicine, Oregon Health & Science University, the University of Pennsylvania, PN, USA.
⁴ The Department of Pathology and Laboratory Medicine and the Knight Cancer Institute at Oregon Health & Science University, the University of Pennsylvania, PN, USA.
⁵ Department of Medicine and the Abramson Cancer Center, the University of Pennsylvania, PN, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Autophagy / drug effects*
Bone Marrow / pathology
Cell Line, Tumor
Drug Resistance, Neoplasm
Female
Humans
Hydroxychloroquine / pharmacology*
Male
Middle Aged
Multiple Myeloma / drug therapy
Multiple Myeloma / metabolism*
Multiple Myeloma / pathology*
Protein Kinase Inhibitors / pharmacology*
Recurrence
Signal Transduction / drug effects
TOR Serine-Threonine Kinases / antagonists & inhibitors*
TOR Serine-Threonine Kinases / metabolism

Substances

Protein Kinase Inhibitors
Hydroxychloroquine
TOR Serine-Threonine Kinases

Grants and funding